THERAFLU WARMING RELIEF FLU AND SORE THROAT OTC
Generic Name and Formulations:
Acetaminophen 325mg, diphenhydramine HCl 12.5mg, phenylephrine HCl 5mg; per 15mL; liq; contains potassium 5mg/15mL, sodium 7mg/15mL; cherry flavor.
Novartis Consumer Health
Indications for THERAFLU WARMING RELIEF FLU AND SORE THROAT :
Minor aches and pains. Headache. Fever. Sneezing. Rhinorrhea. Nasal and sinus congestion. Itchy eyes, nose, throat. Sore throat.
30mL every 4 hours. Max 180mL/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen, diphenhydramine (including skin) products.
Liver disease. Heart disease. Hypertension. Thyroid disease. Diabetes. Glaucoma. COPD. Asthma. GI or GU obstuction. Pregnancy. Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers increase pressor effect of sympathomimetics. Antagonizes antihypertensives. Increased CNS effects with other CNS depressants.
Analgesic + antihistamine + sympathomimetic.
Drowsiness, nervousness, dizziness, insomnia, anticholinergic effects, excitability in children; hepatotoxicity (overdosage).
Endocrinology Advisor Articles
- Soluble Klotho Levels Predictive of Kidney Failure in Type 2 Diabetes
- HbA1c Levels Predictive of Liraglutide Treatment Response in T2D
- Comorbid and Pharmacologic Factors Increase Risk for Gastrointestinal Disorders in Diabetes
- ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes
- Clinicians May Be Overtreating Older Patients With Diabetes
- USPSTF Issues Recommendation for Vitamin D, Calcium Supplementation for Fracture Prevention
- Obesity Risk in Infants Born to Women With Diabetes
- Insulin-Treated Diabetes Reduces Dysglycemia-Related Mortality in Sepsis
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Oxyntomodulin Augments Glucose Homeostasis